الصفحة الرئيسية>>Signaling Pathways>> GPCR/G protein>> Endothelin Receptor>>Avosentan

Avosentan

رقم الكتالوجGC11405

Products are for research use only. Not for human use. We do not sell to patients.

Avosentan التركيب الكيميائي

Cas No.: 290815-26-8

الحجم السعر المخزون الكميّة
5mg
92٫00
متوفر
10mg
126٫00
متوفر
50mg
586٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist.IC50 value:Target: ETA receptor

References:
[1]. Baltatu OC, Iliescu R, Zaugg CE, Reckelhoff JF, Louie P, Schumacher C, Campos LA.Antidiuretic effects of the endothelin receptor antagonist avosentan.Front Physiol. 2012;3:103.
[2]. Konieczka K, Meyer P, Schoetzau A, Neutzner A, Mozaffarieh M, Flammer J.Effect of avosentan (SPP-301) in porcine ciliary arteries.Curr Eye Res. 2011 Feb;36(2):118-24.
[3]. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group.J Am Soc Nephrol. 2010 Mar;21(3):527-35.
[4]. Dieterle W, Hengelage T.Absolute bioavailability and pharmacokinetics of avosentan in man.Int J Clin Pharmacol Ther. 2009 Sep;47(9):587-94.
[5]. Effect of SPP 301, an Endothelin Antagonist, on Intraocular Pressure in Glaucomatous Monkey Eyes By Wang, Rong-Fang; Podos, Steven M.; Serle, Janet B.; Baltatu, Ovidiu C. From Current Eye Research (2011), 36(1), 41-46.

مراجعات

Review for Avosentan

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Avosentan

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.